Menu Close

Northwestern Mutual Wealth Management Co. Boosts Holdings in Insulet Co. (NASDAQ:PODD)

Northwestern Mutual Wealth Management Co. grew its position in shares of Insulet Co. (NASDAQ:PODDGet Rating) by 280.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 323 shares of the medical instruments supplier’s stock after purchasing an additional 238 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Insulet were worth $86,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PODD. Pinebridge Investments L.P. purchased a new stake in shares of Insulet during the fourth quarter valued at approximately $27,000. Confluence Wealth Services Inc. purchased a new stake in shares of Insulet during the fourth quarter valued at approximately $28,000. Wolff Wiese Magana LLC raised its stake in shares of Insulet by 153.6% during the first quarter. Wolff Wiese Magana LLC now owns 142 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 86 shares during the period. Washington Trust Advisors Inc. grew its position in shares of Insulet by 153.7% during the first quarter. Washington Trust Advisors Inc. now owns 208 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 126 shares in the last quarter. Finally, Leverty Financial Group LLC acquired a new stake in shares of Insulet during the fourth quarter worth approximately $62,000.

Insider Buying and Selling at Insulet

In other Insulet news, EVP Bret Christensen sold 2,900 shares of the firm’s stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total value of $766,296.00. Following the sale, the executive vice president now directly owns 19,551 shares in the company, valued at $5,166,156.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the sale, the director now directly owns 13,695 shares in the company, valued at $3,052,615.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Bret Christensen sold 2,900 shares of Insulet stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $264.24, for a total transaction of $766,296.00. Following the sale, the executive vice president now owns 19,551 shares in the company, valued at $5,166,156.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,900 shares of company stock worth $5,401,716. 0.90% of the stock is owned by insiders.

Insulet Stock Performance

PODD stock opened at $267.17 on Friday. The company has a debt-to-equity ratio of 3.28, a quick ratio of 3.54 and a current ratio of 4.69. The stock has a market capitalization of $18.54 billion, a price-to-earnings ratio of 534.34 and a beta of 0.73. Insulet Co. has a 1 year low of $181.00 and a 1 year high of $324.81. The stock’s fifty day moving average is $243.50 and its two-hundred day moving average is $239.48.

Insulet (NASDAQ:PODDGet Rating) last posted its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.72). The company had revenue of $299.40 million during the quarter, compared to the consensus estimate of $290.87 million. Insulet had a net margin of 2.94% and a return on equity of 13.83%. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 earnings per share. On average, research analysts predict that Insulet Co. will post 0.87 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group raised their price target on shares of Insulet from $250.00 to $290.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. BTIG Research raised their price target on shares of Insulet to $285.00 in a research report on Tuesday, August 9th. Canaccord Genuity Group raised their price target on shares of Insulet from $250.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 8th. Morgan Stanley raised their price target on shares of Insulet from $244.00 to $273.00 and gave the stock an “equal weight” rating in a research report on Monday, August 8th. Finally, Wells Fargo & Company decreased their price target on shares of Insulet from $357.00 to $345.00 in a research report on Friday, May 6th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average target price of $295.23.

Insulet Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Read More

Receive News & Ratings for Insulet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Insulet and related companies with MarketBeat.com’s FREE daily email newsletter.